BioVie Announces That Blinded Data Presented Suggest That NE3107 Is Biologically Active And May Have Impact On Cognitive, Biomarker, And Imaging Endpoints Among Mild To Moderate Alzheimer's Disease Patients At CTAD
Portfolio Pulse from Benzinga Newsdesk
BioVie Inc. (NASDAQ:BIVI) has presented blinded data from its Phase 3 clinical trial of NE3107 for the treatment of mild to moderate Alzheimer's Disease. The data suggests that NE3107 is biologically active and may have an impact on cognitive, biomarker, and imaging endpoints. Statistically significant population changes from baseline were observed for all primary and secondary cognitive and functional assessments measured. The company expects to announce unblinded, topline data from this trial in late November or early December.
October 25, 2023 | 4:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioVie's Phase 3 trial data suggests that NE3107 may have a positive impact on Alzheimer's patients. This could potentially lead to increased interest in the company's stock as investors anticipate the release of unblinded data.
The news of positive trial data is typically well-received by investors as it indicates progress in the company's product development. The anticipation of unblinded data release could also drive up the stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100